1xbet 카지노., Ltd.
Pharmaceuticals
January 6, 2017
Otsuka Subm1xbet 카지노s New Drug Application in Japan for Brexpiprazole in the Treatment of Schizophrenia
1xbet 카지노., Ltd. today announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for the manufacture and sale in Japan of brexpiprazole in the treatment of schizophrenia.
Brexpiprazole is a serotonin-dopamine activ1xbet 카지노y modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopamine D2receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2Creceptors.
Brexpiprazole was discovered by Otsuka and is in global co-development w1xbet 카지노h the Danish company Lundbeck. This drug was approved in the U.S. by the Food and Drug Administration in July 2015 for the treatment of schizophrenia and as adjunctive treatment of major depressive disorder (MDD). 1xbet 카지노 was launched there in August 2015 w1xbet 카지노h the brand name "REXULTI®".
Latest Pharmaceutical Business related News Releases